当前位置:
X-MOL 学术
›
ACS Appl. Mater. Interfaces
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Sorafenib-Conjugated Zinc Phthalocyanine Based Nanocapsule for Trimodal Therapy in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model
ACS Applied Materials & Interfaces ( IF 9.5 ) Pub Date : 2020-04-02 , DOI: 10.1021/acsami.0c00375 Xiang-Nan Yu 1, 2 , Yong Deng 3 , Guang-Cong Zhang 1, 2 , Jie Liu 3 , Tao-Tao Liu 1, 2 , Ling Dong 1, 2 , Chang-Feng Zhu 1, 2 , Xi-Zhong Shen 1, 2, 4 , Yu-Hao Li 3 , Ji-Min Zhu 1, 2
ACS Applied Materials & Interfaces ( IF 9.5 ) Pub Date : 2020-04-02 , DOI: 10.1021/acsami.0c00375 Xiang-Nan Yu 1, 2 , Yong Deng 3 , Guang-Cong Zhang 1, 2 , Jie Liu 3 , Tao-Tao Liu 1, 2 , Ling Dong 1, 2 , Chang-Feng Zhu 1, 2 , Xi-Zhong Shen 1, 2, 4 , Yu-Hao Li 3 , Ji-Min Zhu 1, 2
Affiliation
Sorafenib, a multitargeted kinase inhibitor, has been reported to elicit a limited therapeutic effect in hepatocellular carcinoma (HCC). Currently, phototherapy, including photodynamic therapy (PDT) and photothermal therapy (PTT), is emerging as a powerful modality for cancer therapy. However, few studies have been reported the effectiveness of the combination of sorafenib with PDT and PTT in HCC. Herein, we designed and synthesized bovine serum albumin (BSA)-coated zinc phthalocyanine (ZnPc) and sorafenib (SFB) nanoparticle (ZnPc/[email protected]). The obtained ZnPc/[email protected] was able to trigger PDT, PTT, and chemotherapy. After irradiation by a 730 nm light, ZnPc/[email protected] significantly suppressed HCC cell proliferation and metastasis while promoted cell apoptosis in vitro. Furthermore, intravenous injection of ZnPc/[email protected] led to dramatically reduced tumor growth in an orthotopic xenograft HCC model. More importantly, ZnPc/[email protected] presented low toxicity and adequate blood compatibility. Therefore, a combination of ZnPc with sorafenib via BSA-assembled nanoparticle can markedly suppress HCC growth, representing a promising strategy for HCC patients.
中文翻译:
索拉非尼偶联的酞菁锌基纳米胶囊用于原位肝细胞癌异种移植小鼠模型的三峰治疗。
索拉非尼是一种多靶点激酶抑制剂,据报道在肝细胞癌(HCC)中引起有限的治疗作用。当前,包括光动力疗法(PDT)和光热疗法(PTT)在内的光疗法正在成为一种强大的癌症疗法。然而,很少有研究报道索拉非尼与PDT和PTT联合使用在肝癌中的有效性。本文中,我们设计并合成了牛血清白蛋白(BSA)涂层的锌酞菁锌(ZnPc)和索拉非尼(SFB)纳米粒子(ZnPc / [电子邮件保护])。获得的ZnPc / [电子邮件保护]能够触发PDT,PTT和化学疗法。在730 nm的光照射后,ZnPc / [电子邮件保护]显着抑制了HCC细胞的增殖和转移,同时促进了体外细胞凋亡。此外,在原位异种移植HCC模型中,静脉注射ZnPc / [电子邮件保护]导致肿瘤生长显着减少。更重要的是,ZnPc / [受电子邮件保护]具有低毒性和足够的血液相容性。因此,通过BSA组装的纳米颗粒将ZnPc与索拉非尼结合可以显着抑制HCC的生长,这代表了HCC患者的一种有希望的策略。
更新日期:2020-04-03
中文翻译:
索拉非尼偶联的酞菁锌基纳米胶囊用于原位肝细胞癌异种移植小鼠模型的三峰治疗。
索拉非尼是一种多靶点激酶抑制剂,据报道在肝细胞癌(HCC)中引起有限的治疗作用。当前,包括光动力疗法(PDT)和光热疗法(PTT)在内的光疗法正在成为一种强大的癌症疗法。然而,很少有研究报道索拉非尼与PDT和PTT联合使用在肝癌中的有效性。本文中,我们设计并合成了牛血清白蛋白(BSA)涂层的锌酞菁锌(ZnPc)和索拉非尼(SFB)纳米粒子(ZnPc / [电子邮件保护])。获得的ZnPc / [电子邮件保护]能够触发PDT,PTT和化学疗法。在730 nm的光照射后,ZnPc / [电子邮件保护]显着抑制了HCC细胞的增殖和转移,同时促进了体外细胞凋亡。此外,在原位异种移植HCC模型中,静脉注射ZnPc / [电子邮件保护]导致肿瘤生长显着减少。更重要的是,ZnPc / [受电子邮件保护]具有低毒性和足够的血液相容性。因此,通过BSA组装的纳米颗粒将ZnPc与索拉非尼结合可以显着抑制HCC的生长,这代表了HCC患者的一种有希望的策略。